Fluxergy, Mass General Brigham Partner to Evaluate Rapid COVID-19 Molecular Testing System

“Fluxergy is proud to work with Mass General Brigham, one of the nation’s most respected healthcare systems, to assist in evaluating the efficacy of the Fluxergy COVID-19 PCR test,” said Dr. Ali Tinazli, Fluxergy’s Chief Commercialization Officer.

NEW YORK – Fluxergy said on Monday that it is collaborating with Mass General Brigham (MGB, formerly Partners Healthcare) to evaluate Fluxergy’s research-use-only COVID-19 molecular testing platform.

Fluxergy, based in Irvine, California, will specifically work with the MGB Center for COVID Innovation, said Fluxergy Chief Commercialization Officer Ali Tinazli.

The center was launched in late March and is led by Wyss Institute core faculty member David Walt and Massachusetts General Hospital researcher Guillermo Tearney. Walt also spearheads the so-called Diagnostic Accelerator, a collaboration between the Wyss Institute and Brigham and Women’s Hospital that aims to speed up the commercialization of innovative diagnostic tests.

Fluxergy’s diagnostic system comprises consumable “lab-on-chip” test cartridges called Fluxergy Cards, the Fluxergy Analyzer, and FluxergyWorks software, and can provide results in under an hour. Fluxergy Cards are designed to be cost-effective and scalable, using proprietary printed circuit board manufacturing and microfluidics technologies, according to the company. FluxergyWorks, meanwhile, enables organizations to link as many as 256 Fluxergy Analyzers via the cloud for centralized data reporting.

Tinazli said that Fluxergy has submitted a PCR-based COVID-19 test for Emergency Use Authorization from the US Food and Drug Administration. However, the collaboration with MGB will be for research use only. Tinazli added that the company is also developing the system to be able to simultaneously run molecular and immunoassay diagnostic tests.

In March, Fluxergy announced that it was similarly working with a team at the University of California, San Diego, to evaluate its system for COVID-19 testing. That effort is being led by Davey Smith, professor of medicine and head of the UCSD Division of Infectious Diseases and Global Public Health, as well as a member of Fluxergy’s medical advisory board.

Read the article here: https://www.genomeweb.com/pcr/fluxergy-mass-general-brigham-partner-evaluate-rapid-covid-19-molecular-testing-system#.Xvt_dShKg2w


Share on linkedin
Share on twitter
Share on email
Share on facebook
Share on reddit

Fluxergy Corporate Campus

US Headquarters
30 Fairbanks, Irvine, CA 92618
+1(949) 305-4201

R&D Center
13766 Alton Pkwy, Irvine, CA 92618

Manufacturing Center
15 Musick, Irvine, CA 92618

Fluxergy Europe GmbH i.G.
Eichenstr. 4  63667 Nidda, Germany
+49 6043 403518

*Only Fluxergy Test Kit COVID-19 has been approved for CE-IVD and is available for any markets that accept CE marking as the valid regulatory approval.

All other products or any other markets are For Research Use Only (RUO) and are not for use in diagnostic procedures.

*This website is governed by applicable U.S. laws and governmental regulations. The products and information contained herewith may not be accessible in all countries, and Fluxergy takes no responsibility for such information which may not comply with local country legal process, regulation, registration and usage.

*Although forward-looking statements contained in this website regarding Fluxergy’s objectives, plans, goals, strategies, future growth, business prospects and opportunities are based upon what Fluxergy management believes are reasonable assumptions, estimates, and other judgments, there can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements.

Copyright 2022 Fluxergy